<DOC>
	<DOCNO>NCT02292121</DOCNO>
	<brief_summary>In rodent , obesity associate change tight junction ' structure small intestine , impact intestinal permeability result metabolic complication . Few data exist human . We hypothesize intestinal permeability alter obese subject comparison lean subject , link metabolic inflammatory status alteration modify gastric bypass .</brief_summary>
	<brief_title>Intestinal Permeability Obesity</brief_title>
	<detailed_description>The regulation permeability intestinal barrier essential molecular traffic lumen internal environment . It affect absorption nutrient tolerance immunization foodborne non-self antigen penetrate barrier . In rodent , increase endotoxemia propose important player low-grade inflammation accompany development obesity metabolic disorder . In human , intestinal barrier function alter inflammatory bowel disease ( IBD , Crohn 's disease , ulcerative colitis celiac disease ) . The term `` leaky gut '' use describe porous intestine hyper-permeability associate acute chronic inflammatory diseases `` systemic inflammatory response syndrome ( SIRS ) , '' acute inflammatory bowel disease ( IBD `` inflammatory bowel disease '' ) . Deficiencies barrier also observe extra-intestinal disease ( type-1 diabetes , food allergy , autoimmune disease ) . Impairments tight junction may precede clinical sign constitute risk factor develop disease secondarily alter cause increase entry undesirable bacterial nutritional antigen . The state intercellular tight junction intestine control diffusion molecule cell . A deficiency intestinal barrier function often associate structural change tight junction result loss localization protein expression gene / cellular signal ZO-1 , occludin tricellulin . There study condition intestinal barrier context human obesity . The objective study : - compare intestinal permeability obese subject non obese subject gastric bypass . - search link intestinal permeability 1 ) metabolic inflammatory bioclinical parameter 2 ) dietary profile 3 ) microbiota</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Nutrition Disorders</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Inclusion criterion : Control subject T1 : 1 . Registered social security 2 . Signed consent form 3. male female subject 18 65 year old 4 . Fasting plasma triglyceride &lt; 1.5 g/l ( &lt; 1.7 mmol/l ) 5 . Fasting plasma total cholesterol &lt; 2.5 g/l ( &lt; 6 mmol/l ) 6. fast glycaemia &lt; 5,5 mmol/l 7 . BMI &lt; 25kg/m² &amp; &gt; 18 kg/m² 8 . Mean systolic blood pressure &lt; 140 mmHg mean diastolic blood pressure &lt; 90 mmHg . Control subject T2 1 . Registered social security 2 . Signed consent form 3. male female subject 18 70 year old 4 . IMC &lt; 25kg/m² et &gt; 18 kg/m² 5. candidate surgery give access jejunal sample Obese subject OB : 1 . Registered social security 2 . Signed consent form 3. male female subject 18 65 year old 4 . Candidate bariatric surgery ( bypass ) massive ( IBMI &gt; = 40 kg/m² ) severe obesity ( BMI 35 &amp; 40 kg/m² ) least one obesityrelated comorbidity stable weight ( +/5kg ) last 3 month , approval multidisciplinary team Exclusion criterion : Control subject T1 : 1 . Subject history vascular symptomatic disease last 6 month selection . 2 . Subject receive treatment affect measure parameter 3 . Pregnancy 4 . Subject acute chronic disease affect measure parameter lifethreatening . Including limited : 1 . Diabetic subject 2 . Subject kidney disease : nephrotic syndrome , chronic renal failure 3 . Subject gastrointestinal disorder disease limit intestinal absorption ( celiac disease ) , bariatric surgery . 4 . Active inflammatory disease history IBD 5 . Subject situation , accord investigator 's opinion could interfere optimal participation study constitute particular risk subject 6 . Subject exclusion period participate another clinical trial 7 . Adult person subject legal protection unable consent . 8 . Persons deprive liberty judicial administrative decision Control subject T2 1 . Subject history symptomatic vascular disease ( myocardial infarction , angina syndrome threat , surgical endovascular surgery , stroke , low limb arteritis symptomatic ) less 6 month 2 . Subject acute chronic disease may influence result study lifethreatening . Including limiting : 1. diabetic patient 2 . Subject kidney disease : nephrotic syndrome , chronic renal failure / serum creatinine &gt; 1.7 time upper limit reference value 3 . Adult person subject legal protection unable consent . 4 . Persons deprive liberty judicial administrative decision Obese subject candidate surgery : 1 . Subject receive treatment systemically topically , may interfere evaluation parameter study ( NSAIDs , antibiotics previous month ) 2 . Any disease psychosocial context make prolonged regular monitoring impossible , also represent contraindication bariatric surgery . 3 . Adult person subject legal protection unable consent . 4 . Persons deprive liberty judicial administrative decision</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Intestinal permeability</keyword>
	<keyword>Adipose tissue inflammation</keyword>
	<keyword>Low grade systemic inflammation</keyword>
	<keyword>Bariatric surgery</keyword>
</DOC>